Publication: Inhibidores de la quinasa GSK-3β en el tratamiento de la enfermedad de Alzheimer
Loading...
Official URL
Full text at PDC
Publication Date
2016
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
La enfermedad de Alzheimer (EA) es una de las enfermedades neurodegenerativas más relevantes en la actualidad, cuya incidencia aumenta progresivamente y para la cual no se dispone de tratamiento efectivo alguno. Debido al desconocimiento de su etiopatogénesis exacta, han surgido diversas líneas de investigación basadas en la búsqueda de fármacos que curen la enfermedad. De entre las numerosas hipótesis existentes, parece ser que el fenómeno de hiperfosforilación de tau es uno de los más influyentes y característicos de la EA. Por esta razón se ha definido a la quinasa GSK-3β (responsable de esta fosforilación) como una de las dianas más prometedoras en la carrera por el desarrollo de compuestos farmacológicos de utilidad terapéutica, capaces de inhibir al enzima y, por tanto, detener el progreso de la EA.
Alzheimer’s disease (AD) is one of the most relevant neurodegenerative diseases nowadays, whose incidence shows a progressive increase and to whom there is no effective treatment available. Due to the fact that its exact etiopathogenesis remains still unknown, several research pathways, based on the seek for curative drugs, have emerged. Among the amount of existing hypothesis, it seems that the hyperphosphorylation of tau is one of the most influent and characteristic features of the AD. Therefore, the kinase known as GSK-3β (responsible for this phosphorylation) has been established as one of the most promising targets in the race for the development of different useful pharmacological compounds, whose ability to inhibit the enzyme allows them to halt the progression of the AD.
Alzheimer’s disease (AD) is one of the most relevant neurodegenerative diseases nowadays, whose incidence shows a progressive increase and to whom there is no effective treatment available. Due to the fact that its exact etiopathogenesis remains still unknown, several research pathways, based on the seek for curative drugs, have emerged. Among the amount of existing hypothesis, it seems that the hyperphosphorylation of tau is one of the most influent and characteristic features of the AD. Therefore, the kinase known as GSK-3β (responsible for this phosphorylation) has been established as one of the most promising targets in the race for the development of different useful pharmacological compounds, whose ability to inhibit the enzyme allows them to halt the progression of the AD.